Biotech Award – January 23, 2026
The aim of the initiative is to strengthen research in rare diseases where access to data and analytical tools remains limited.
CDMO – January 23, 2026
Diamyd Medical is taking the next step in a long-term manufacturing collaboration with APL and, in parallel, is initiating a strategic collaboration with NorthX Biologics to further develop and scale the manufacturing of retogatein (rhGAD65) ahead of commercialization.
Financing – January 22, 2026
Life Science Invest’s sixth co-investment company, LSI Zeta, has raised EUR 2.9 million from 35 Nordic business angels.
Science News – January 21, 2026
The World Economic Forum’s Top 10 Emerging Technologies of 2025 report explores the technologies that are set to have a significant impact on our lives, here are the ones with life science applications.
Business article – January 21, 2026
Lithuanian company Biomatter is an enzyme design company that bridges the gap between generative AI and real-world industrial applications.
Global report – January 21, 2026
Women’s health only receives 6% of private healthcare investment despite women representing almost half of the global population, according to a new World Economic Forum report, launched January 20 2026.

Opinion & debate
Clinical Trials – January 12, 2026
Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.
Clinical Trials – January 9, 2026
Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.
Clinical Trials – January 8, 2026
Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson’s disease, states the company.
Clinical Trials – January 7, 2026
BioInvent International has announced encouraging interim results from its ongoing Phase 2a signal-seeking study evaluating BI-1808, a novel immuno-oncology candidate, in combination with MSD’s anti-PD-1 therapy KEYTRUDA in patients with recurrent ovarian cancer who have progressed following platinum-based therapy.
Clinical Trials – January 2, 2026
Hemab Therapeutics has announced positive results from its completed Phase 2 multiple ascending dose (MAD) portion of the CL-101 study of sutacimig for the prophylactic treatment of Glanzmann thrombasthenia (GT).
Clinical Trials – December 17, 2025
Zelluna has announced the publication of preclinical data for its lead candidate, ZI-MA4-1, in the peer-reviewed journal Immunotherapy Advances.
Agreement – January 21, 2026
The company has entered into an exclusive global licensing and research collaboration with a multinational consumer health company to expand the SiPore technology platform into consumer oral health through a partner-led approach.
Biotech Business – January 20, 2026
The Board of Directors of the company has resolved to carry out a fully guaranteed rights issue of SEK 307 million.
Global report – January 14, 2026
AstraZeneca is acquiring its AI partner Modella AI to own and deploy multimodal AI foundation models in‑house across discovery and development.
Agreement – January 20, 2026
The two companies have entered into an agreement regarding the use of the OnDosis drug delivery platform, the Dosage Manager, in Diamond’s psychoactive low-dose psilocybin programs.
Biotech Business – January 13, 2026
Thus, Evaxion will in the future work within cancers, infectious and autoimmune diseases as its core disease areas.
MedTech Business – January 2, 2026
The Board of Directors of Episurf Medical has entered into an agreement with Goldcup 38657 AB regarding the acquisition of all shares in Goldcup 38658 AB, a wholly owned subsidiary of the seller.
Biotech Business – January 20, 2026
AAX Biotech will leverage its Seqitope platform and automation infrastructure to accelerate antibody characterization, driving faster, data-driven insights across drug discovery and development.
Biotech article – January 7, 2026
The Biotech Act is an initiative to strengthen Europe’s competitiveness in biotechnology and drug development.
Biotech Business – January 2, 2026
Consequently, Evaxion retains global rights to EVX-B2 and will look for another potential licensing partner.
Science article – January 14, 2026
With lack of diversity and cross-border collaborations, we not only lose out on innovation – we jeopardize our democracy and risk losing an important driving force in promoting peace.
Science News – January 14, 2026
The Research Council of Finland (RCF) has allocated a total of 27.5 million euros for the recruitment of top-level researchers from outside Finland.
Funding – January 14, 2026
The scientists will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus. Funding from CEPI and the European Union’s Horizon Europe programme Backed by up to USD 26.7 million in funding from CEPI and the European Union’s Horizon […]
Stryker
Looking for a place that values your unique talents? Discover Stryker’s award-winning culture.
Confidential
PharmaRelations, together with the Board of Directors, are seeking an experienced and visionary CEO to lead a rapidly growing Life Science company through its next phase of development and growth. The company is based in southern Sweden.
Stryker
Looking for a place that values your unique talents? Discover Stryker’s award-winning culture.
GEA Process Engineering
GEA – “Engineering for a better world”. GEA, one of the world’s largest systems suppliers for the Food, Beverage, and Pharmaceutical sectors.
PharmaRelations
This is a leadership position that combines strategic oversight, business development, and team leadership. The successful candidate will play a pivotal role in shaping our pharmacovigilance and safety functions across both clinical and post-marketing environments.
dsm-firmenich
dsm-firmenich is your innovation partner in all things: nutrition, health and beauty.
In a new job – January 9, 2026
AstraZeneca’s new head of Investor Relations, Joris Silon, succeeds Andy Barnett on 1 March 2026, and will be based in Cambridge, UK.
In a new job – January 8, 2026
Q-linea has announces that Jim Kathrein will step down as VP US Commercial Operations.
In a new job – January 6, 2026
Alvotech has announced key senior leadership changes following a planned succession process.
Careers article – January 15, 2026
A large international study published in The Lancet, suggests that adding just five minutes of moderate-intensity activity per day – or cutting sitting time by 30 minutes – could prevent a substantial share of premature deaths.
Careers article – January 12, 2026
When working, many of us sit for long periods of time, especially at desks and in front of screens.
Biotech Business – December 15, 2025
Hansa Biopharma has announced a reorganization of its European and International Commercial and Medical Affairs operations, effective December 11, 2025.
Profiles in Business – December 8, 2025
Successful businessman and former chairman of AstraZeneca, Leif Johansson, has accumulated vast experience and knowledge about international competition, leadership, business development, and entrepreneurship, not least when it comes to science-driven industries like the life science industry.
Nobel Prize 2025 – November 25, 2025
With a family legacy in medicine dating back to the Shogun era, the Japanese immunologist Dr. Shimon Sakaguchi has dedicated his career to the science. A 30-year-old pivotal discovery led him to this year’s Nobel Prize in Physiology or Medicine for research in peripheral immune tolerance.
Nobel Prize 2025 – November 25, 2025
Nobel Prize laureate Mary E. Brunkow’s career path has shifted between industry and academia but her end goal to generate clinical benefit and her passion for exploring new areas have never wavered.
Upcoming events
This site uses cookies